CEO Anthony Hayes Buys 38,208 Of Aikido Pharma At An Average Price Of $6.33
$AIKI
Specialty Chemicals
Consumer Discretionary
- Dow Jones
- Dow Jones
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/11/2021 | $2.00 | Buy | HC Wainwright & Co. |
4 - Dominari Holdings Inc. (0000012239) (Issuer)
4 - Dominari Holdings Inc. (0000012239) (Issuer)
4 - Dominari Holdings Inc. (0000012239) (Issuer)
4 - Dominari Holdings Inc. (0000012239) (Issuer)
4 - Dominari Holdings Inc. (0000012239) (Issuer)
4 - Dominari Holdings Inc. (0000012239) (Issuer)
8-K - Dominari Holdings Inc. (0000012239) (Filer)
8-K - Dominari Holdings Inc. (0000012239) (Filer)
10-Q - Dominari Holdings Inc. (0000012239) (Filer)
SC 13D - Dominari Holdings Inc. (0000012239) (Subject)
SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)
SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)
NEW YORK, Dec. 28, 2022 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today provided an update on the $2 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on December 5, 2022. The Company reported that on December 27, 2022, the Company purchased 4,000 shares of common stock at $3.1012 per share. Anthony Hayes, CEO of Dominari, stated, "The Company's stock is trading at levels we believe are below its intrinsic value. To enhance shareholder value, we are making purchases as part
NEW YORK, Dec. 22, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) (the "Company") today announced that it has changed its name from AIkido Pharma Inc. to Dominari Holdings Inc. and its ticker symbol from "AIKI" to "DOMH." The Company expects that its shares of common stock will begin trading on The Nasdaq Stock Market under the new name and new stock ticker symbol "DOMH" on or about December 22, 2022. The name change was approved at a meeting of the board of directors held on December 5, 2022. Anthony Hayes, CEO of Dominari Holdings Inc., commented, "Rebranding of the C
Leading Advanced Materials Company Now Listed on NASDAQ under the symbol, ASPI NEW YORK, Nov. 28, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced the successful initial public offering ("IPO") of ASP Isotopes ("ASPI"). ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses. The shares began trading on the Nasdaq Capita
NEW YORK, June 23, 2021 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced that the Company has filed a provisional patent application for the use of ketamine and peptides to treat Alzheimer's disease. The Company previously secured and announced the acquisition of patent rights for use of peptides as a drug delivery system. This patent application seeks patent protection for the use of ketamine and these peptides to treat Alzheimer's disease. We believe that one of the biggest breakthroughs in the study of depression has been the ob
HC Wainwright & Co. initiated coverage of AIkido Pharma with a rating of Buy and set a new price target of $2.00
The Dow Jones closed higher by over 100 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. IN8bio The Trade: IN8bio, Inc. (NASDAQ:INAB) 10% owner BIOS Advisors GP, LLC bought a total of 75,001 shares at an average price of $2.48. To acquire these shares, it cost around $185.91 th
HC Wainwright & Co. analyst Vernon Bernardino maintains AIkido Pharma (NASDAQ:AIKI) with a Buy and lowers the price target from $36 to $16.
-Reuters
New Director Supports NASDAQ Rule on Diversity NEW YORK, June 10, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today announced the appointment of Ms. Soo Yu, as a director of the Company. Anthony Hayes, CEO of AIkido stated, "At the time of the annual meeting, there was concern expressed by some shareholders about the Company's compliance with the new NASDAQ rules on diversity. The Company strongly believes in diversity and Ms. Yu is an exceptional candidate that also satisfies the new NASDAQ rule. Further, Ms. Yu's background broadens t
NEW YORK, Sept. 14, 2021 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ:AIKI) ("AIkido" or the "Company") today released the following shareholder update: Dear Shareholder, September is an opportune time to provide a shareholder and investor update and we are pleased to report on positive developments and near-term upcoming potential value creating catalysts. To start, we are pleased to announce that last month, DatChat Inc., (NASDAQ:DATS) went public. AIkido owns 525,000 shares of DatChat, which it previously purchased for $500,000.00. As of September 13th, DatChat shares closed at $6.54, well higher than its IPO price and representing a more than 600% return or an additional $3,433,500.00 ad
NEW YORK, April 5, 2021 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided a business update. Anthony Hayes, CEO of AIkido Pharma, stated, "AIkido's primary focus is the commercialization of improved treatments for multiple types of cancer and viral infections through innovative research and development that leverages the power of artificial intelligence and machine learning. Our research partners continue to make progress towards this focus with positive results in ongoing preclinical studies. In addition, through a series of financing transactions over the course of 2020, and the last several months, we are sufficiently capitalized to support our